Reeves, Iain

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

McCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., Sullivan, A. K., Clarke, A., Reeves, I., Schembri, G., et al. (2016) · The Lancet

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 1,878

An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.

On behalf of the PROUD Study Group, Dolling, D. I., Desai, M., McOwan, A., Gilson, R., Clarke, A., Fisher, M., Schembri, G., Sullivan, A. K., Mackie, N., et al. (2016) · Trials

HIV/AIDS Research and InterventionsHIV, Drug Use, Sexual Risk

Cited by 51

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial

Moyle, G., Assoumou, L., de Castro, N., Post, F. A., Curran, A., Rusconi, S., De Wit, S., Stephan, C., Raffi, F., Johnson, M., et al. (2024) · The Lancet HIV

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 6